The real-world analysis of Tecartus showed ORR (90%) which was similar to (ZUMA-2) study results at the median follow-up of 12mos., CR (78%), DoR (64%), PFS (61%) & OS rates (74%) at 12mos., grade ≥3 CRS and ICANS incidence were 10% & 28%, respectively
In a multivariate analysis, ORR (94%) & CR (88%) who received Tecartus in earlier lines of therapy (1-2 vs ≥3 prior lines of therapy), PFS was improved in patients with prior autoHCT over without prior autoHCT
In BTKi-naïve patients, effectiveness (ORR 92%, CR 83%) and safety outcomes are consistent over prior BTKi-treated patients. In patients with prior bendamustine use, effectiveness remained consistent, reduction in risk of grade ≥3 ICANS & an increased risk of prolonged thrombocytopenia
Ref: Businesswire | Image: Kite
Related News:- Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
